<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02227550</url>
  </required_header>
  <id_info>
    <org_study_id>AFNET 5 AXAFA</org_study_id>
    <secondary_id>2014-002442-45</secondary_id>
    <nct_id>NCT02227550</nct_id>
  </id_info>
  <brief_title>Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy</brief_title>
  <acronym>AXAFA</acronym>
  <official_title>An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrial Fibrillation Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective is to demonstrate that anticoagulation with the direct factor Xa inhibitor
      apixaban is not less safe than Vitamin-K-antagonists (VKA) therapy in patients undergoing
      catheter ablation of non-valvular AF in the prevention of peri-procedural complications.

      The AXAFA trial will compare peri-ablational treatment with apixaban to peri-ablational
      treatment wit VKA in a randomized trial of patients undergoing catheter ablation of atrial
      fibrillation (AF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AXAFA is an open-label trial designed to evaluate the safety and efficacy of two types of
      anticoagulant therapy, VKA therapy and therapy with the direct factor Xa inhibitor apixaban,
      in patients undergoing scheduled catheter ablation for AF. All patients will undergo the
      ablation procedure after pre-treatment with an anticoagulant (either apixaban in the &quot;Xa
      group&quot; or a vitamin K antagonist in the &quot;VKA group&quot;).

      Patients can undergo catheter ablation within the trial after at least 30 days of continuous
      effective anticoagulation. Ablation can be performed earlier when or timely after exclusion
      of atrial thrombi have been excluded by a clinically indicated by transthoracic
      echocardioggram (TEE). After TEE continuous effective anticoagulation must be ensured until
      the end of the trial.

      In the MRI-substudy will be explored wether novel oral anticoagulants (NOAC) have the
      potential to reduce clinically silent brain lesions after catheter ablation of AF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death and serious cardiovascular events</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>A composite of all-cause death, stroke (ischemic stroke, subarachnoid haemorrhage and haemorrhagic stroke), and major bleeding events, def.as BARC 2 or higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>any bleeding event</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding events acc. to the ISTH and TIMI definitions</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>strokes, other systemic embolic events and all-cause death</measure>
    <time_frame>appr. 4 month</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from randomisation to ablation</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nights spent in hospital after ablation</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-care related cost calculation</measure>
    <time_frame>appr. 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalizations for cardiovascular reasons</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration prior to ablation and total time on oral anticoagulation</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients with clinically indicated TEE</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACT during ablation</measure>
    <time_frame>during ablation</time_frame>
    <description>Active clotting measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrent Atrial Fibrillation (AF)</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>time to recurrent AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rhythm status at the end of follow-up</measure>
    <time_frame>end of follow-up</time_frame>
    <description>rythm status documented by 24 hour Holter ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular access complications leading to prolongation of in-hospital stay or specific therapy</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life changes</measure>
    <time_frame>baseline to 3 month follow-up</time_frame>
    <description>questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function change</measure>
    <time_frame>baseline to 3 month follow-up</time_frame>
    <description>questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinically &quot;silent&quot; MRI-detected brain lesions</measure>
    <time_frame>within 48 hours after ablation procedures</time_frame>
    <description>prevalence (MRI-substudy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of ablation-associated clinically overt strokes or MRI-detected bus clincally &quot;silent&quot; acute brain lesions on cognitive function after ablation</measure>
    <time_frame>appr. 4 months</time_frame>
    <description>MRI-substudy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">676</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xa group: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K antagonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VKA group: any Vitamin K antagonist (VKA), INR 2-3 , min. 30 days prescribed as in clinical routine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist</intervention_name>
    <description>any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin</description>
    <arm_group_label>Vitamin K antagonist</arm_group_label>
    <other_name>warfarin</other_name>
    <other_name>phenprocoumon</other_name>
    <other_name>acecoumaril</other_name>
    <other_name>fluindione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine &gt;= 1.5 mg/dl (133mM), &lt;= 60 kg body weight or age &gt;= 80 years.</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>BMS-562247</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        I1. Non-valvular AF (ECG-documented) with a clinical indication for catheter ablation

        I2. Clinical indication to undergo catheter ablation on continuous anticoagulant therapy

        I3. Presence of at least one of the CHADS2 stroke risk factors

          -  Stroke or TIA

          -  age ≥ 75 years,

          -  hypertension, defined as chronic treatment for hypertension, estimated need for
             continuous antihypertensive therapy or resting blood pressure &gt; 145/90 mm Hg,

          -  diabetes mellitus,

          -  symptomatic heart failure (NYHA ≥ II).

        I4. Age ≥ 18 years

        I5. Provision of signed informed consent

        Exclusion Criteria:

        General exclusion criteria

        E1. Any disease that limits life expectancy to less than 1 year

        E2. Participation in another clinical trial, either within the past two months or still
        ongoing

        E3. Previous participation in AXAFA

        E4. Pregnant women or women of childbearing potential not on adequate birth control: only
        women with a highly effective method of contraception (oral contraception or intra-uterine
        device) or sterile women can be randomised.

        E5. Breastfeeding women

        E6. Drug abuse or clinically manifest alcohol abuse

        E7. Any stroke within 14 days before randomisation

        E8. Coadministration with drugs that are strong dual inhibitors of cytochrome P450 3A4
        (CYP3A4) and P-glycoprotein (P-gp) or strong dual inducers of CYP3A4 and P-gp (Appendix
        VIII).

        Exclusion criteria related to a cardiac condition

        E9. Valvular AF (as defined by the focussed update of the ESC guidelines on AF, i.e. severe
        mitral valve stenosis, mechanical heart valve). Furthermore, patients who underwent mitral
        valve repair are not eligible for AXAFA.

        E10. Any previous ablation or surgical therapy for AF

        E11. Cardiac ablation therapy for any indication (catheter-based or surgical) within 3
        months prior to randomisation

        E12. Clinical need for &quot;triple therapy&quot; (combination therapy of clopidogrel,
        acetylsalicylic acid, and oral anticoagulation)

        E13. Other contraindications for use of VKA or apixaban

        E14. Documented atrial thrombi less than 3 months prior to randomisation.

        Exclusion criteria based on laboratory abnormalities

        E15. Severe chronic kidney disease with an estimated glomerular filtration rate (GFR) &lt; 15
        ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulus Kirchhof, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham Centre for Cardiovascular Scienes, UK and University Hospital Muenster, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsyvlania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cariovascular Research Insititute</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Sites</name>
      <address>
        <city>Different</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5 Sites</name>
      <address>
        <city>Different</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5 Sites</name>
      <address>
        <city>Different</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>13 Sites</name>
      <address>
        <city>Different</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Sites</name>
      <address>
        <city>Different</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>6 Sites</name>
      <address>
        <city>Different</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3 Sites</name>
      <address>
        <city>Different</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4 Sites</name>
      <address>
        <city>Different</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Di Biase L, Callans D, Hæusler KG, Hindricks G, Al-Khalidi H, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace. 2017 Jan;19(1):132-138. doi: 10.1093/europace/euw368.</citation>
    <PMID>28130378</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>August 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrilal fibrillation</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>prevention of peri-procedural complication</keyword>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Factor Xa Inhibitors</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

